Canadian Active & Maintenance Modified Pentasa Study
A Multicentre, Randomised, Double-blind, Non-inferiority Trial Comparing the Efficacy and Safety of a New Modified Oral Extended Release Pentasa® (Mesalamine) 500 mg Tablet to the Currently Marketed Pentasa® (Mesalamine) 500 mg Tablet in Subjects With Active Mild to Moderate Ulcerative Colitis Treated With 4 g/Day for 8 Weeks and in Maintenance of Remission of Ulcerative Colitis in Subjects Treated With 2 g/Day for 24 Weeks A Multicentre, Randomised, Double-blind, Non-inferiority Trial Comparing the Efficacy and Safety of ...
Active Ulcerative Colitis;Remission of Ulcerative Colitis